Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
04:55am, Saturday, 21'st Dec 2024
Since pharmaceutical giant Eli Lilly (LLY 1.35%) reported earnings for the third quarter on Oct. 30, shares have been punished by investors. As of this writing, Lilly's stock price has plunged as much
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
05:58pm, Friday, 20'th Dec 2024
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea. The post Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Di
Zepbound Approved For Sleep Apnea
05:28pm, Friday, 20'th Dec 2024
The Food and Drug Administration approved Zepbound as the first prescription medicine to treat sleep apnea on Friday—marking a significant win for the drug company Eli Lilly, which had Zepbound appr
Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea
04:42pm, Friday, 20'th Dec 2024
The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
04:39pm, Friday, 20'th Dec 2024
The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is now cle
Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms associated w
BMO lowers Novo Nordisk price target to $105, says reaction to data 'overdone'
02:28pm, Friday, 20'th Dec 2024
BMO Capital lowered the firm's price target on Novo Nordisk (NVO) to $105 from $156 and keeps an Outperform rating on the shares after CagriSema's Phase 3 data readout failed to meet investor expectat
Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture
02:05pm, Friday, 20'th Dec 2024
The CNBC 'Halftime Report' Investment Committee discusses today's market movers.
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
12:45pm, Friday, 20'th Dec 2024
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. Tirzepatide's clinical trial updates were very positive this year, including the
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
12:20pm, Friday, 20'th Dec 2024
Bad news for Novo Nordisk (NVO -17.77%) Friday was good news for Eli Lilly (LLY 4.88%) and Viking Therapeutics (VKTX 5.86%), its two main rivals in the field of weight loss drugs. This morning, Novo r
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
11:05am, Friday, 20'th Dec 2024
Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.
Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News Alert
07:45am, Friday, 20'th Dec 2024
SUGAR LAND, Texas--(BUSINESS WIRE)--Thanks largely to some blockbuster projects, the value of industrial construction presently underway in Indiana and tracked by Industrial Info exceeds $39 billion.
Novo Nordisk Stock Crashes 22% After Disappoitning Obesity Drug Data. Eli Lilly Shares Soar.
06:20am, Friday, 20'th Dec 2024
The experimental obesity drug CagriSema disappointed investors.
Focus: In weight loss battle, Novo and Lilly face growing offensive from licenced copies
08:03pm, Thursday, 19'th Dec 2024
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators overseas, posing a threa
US FDA says Lilly's weight-loss drug shortage resolved
10:12am, Thursday, 19'th Dec 2024
The U.S. Food and Drug Administration said on Thursday that Eli Lilly's weight-loss drug shortage has been resolved, following a re-evaluation of the drug's supply by the agency.
